A Phase 1 interventional study of Zemiglo 50mg and Forxiga 10mg and Fixed-dose Combinations of Gemigliptin/Dapagliflozin 50/10 mg in T2DM, sponsored by LG Chem. Status unknown. Open to participants aged 19 Years to 50 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2020-09-11.
Sponsored by LG Chem · Phase 1, Interventional, and Other
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
To identify bioequivalence between Fixed-dose Combinations of Gemigliptin/Dapagliflozin 50/10 mg to Each Component of Gemigliptin 50 mg and Dapagliflozin 10 mg
To identify bioequivalence between Fixed-dose Combinations of Gemigliptin/Dapagliflozin 50/10 mg and each Component of Gemigliptin 50 mg and Dapagliflozin 10 mg Also we identify safety and tolerance of FDC and each component
LG Chem is the lead sponsor of 71 studies on the registry; 8 are open to participants now.
Of its 13 completed or terminated interventional studies of FDA-regulated products, 1 (8%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
These resluts are appeared when screening
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Firstly, administrating each component Gemigliptin 50mg and dapagliflozin 10mg and after resting period administrating Fixed-dose Combinations of Gemigliptin/Dapagliflozin 50/10 mg
Drug: Zemiglo 50mg and Forxiga 10mg · Drug: Fixed-dose Combinations of Gemigliptin/Dapagliflozin 50/10 mg
Firstly, administrating Fixed-dose Combinations of Gemigliptin/Dapagliflozin 50/10 mg and after resting period administrating each component Gemigliptin 50mg and dapagliflozin 10mg
Drug: Zemiglo 50mg and Forxiga 10mg · Drug: Fixed-dose Combinations of Gemigliptin/Dapagliflozin 50/10 mg
Each component of Gemigliptin 50mg QD and Dapagliflozin 10mg QD
Also known as: zemiglo and Forxiga
Fixed-dose Combinations of Gemigliptin/Dapagliflozin 50/10 mg QD
Also known as: zemiglo and Forxiga
Gemigliptin and dapagliflozin AUClast and Cmax
each phase 17 times blood sampling, total 34 times blood sampling
Time frame: Pre-dose (Day1 0 hour)
Gemigliptin and dapagliflozin AUClast and Cmax
each phase 17 times blood sampling, total 34 times blood sampling
Time frame: Day 1 0.25hour
Gemigliptin and dapagliflozin AUClast and Cmax
each phase 17 times blood sampling, total 34 times blood sampling
Time frame: Day 1 0.5hour
Gemigliptin and dapagliflozin AUClast and Cmax
each phase 17 times blood sampling, total 34 times blood sampling
Time frame: Day 1 0.75hour
Gemigliptin and dapagliflozin AUClast and Cmax
each phase 17 times blood sampling, total 34 times blood sampling
Time frame: Day 1 1hour
Gemigliptin and dapagliflozin AUClast and Cmax
each phase 17 times blood sampling, total 34 times blood sampling
Time frame: Day 1 1.5hour
Gemigliptin and dapagliflozin AUClast and Cmax
each phase 17 times blood sampling, total 34 times blood sampling
Time frame: Day 1 2hour
Gemigliptin and dapagliflozin AUClast and Cmax
each phase 17 times blood sampling, total 34 times blood sampling
Time frame: Day 1 3hour
Gemigliptin and dapagliflozin AUClast and Cmax
each phase 17 times blood sampling, total 34 times blood sampling
Time frame: Day 1 4hour
Gemigliptin and dapagliflozin AUClast and Cmax
each phase 17 times blood sampling, total 34 times blood sampling
Time frame: Day 1 6hour
Gemigliptin and dapagliflozin AUClast and Cmax
each phase 17 times blood sampling, total 34 times blood sampling
Time frame: Day 1 8hour
Gemigliptin and dapagliflozin AUClast and Cmax
each phase 17 times blood sampling, total 34 times blood sampling
Time frame: Day 1 10hour
Gemigliptin and dapagliflozin AUClast and Cmax
each phase 17 times blood sampling, total 34 times blood sampling
Time frame: Day 1 12hour
Gemigliptin and dapagliflozin AUClast and Cmax
each phase 17 times blood sampling, total 34 times blood sampling
Time frame: Day 1 24hour
Gemigliptin and dapagliflozin AUClast and Cmax
each phase 17 times blood sampling, total 34 times blood sampling
Time frame: Day 1 36hour
Gemigliptin and dapagliflozin AUClast and Cmax
each phase 17 times blood sampling, total 34 times blood sampling
Time frame: Day 1 48hour
Gemigliptin and dapagliflozin AUClast and Cmax
each phase 17 times blood sampling, total 34 times blood sampling
Time frame: Day 1 72hour
Gemigliptin and dapagliflozin AUCinf
each phase 17 times blood sampling, total 34 times blood sampling
Time frame: Pre-dose (Day1 0 hour), Day 1 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48, 72 hour
Gemigliptin and dapagliflozin Tmax
each phase 17 times blood sampling, total 34 times blood sampling
Time frame: Pre-dose (Day1 0 hour), Day 1 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48, 72 hour
Gemigliptin and dapagliflozin t1/2
each phase 17 times blood sampling, total 34 times blood sampling
Time frame: Pre-dose (Day1 0 hour), Day 1 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48, 72 hour
Gemigliptin and dapagliflozin CL/F
each phase 17 times blood sampling, total 34 times blood sampling
Time frame: Pre-dose (Day1 0 hour), Day 1 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48, 72 hour
Gemigliptin and dapagliflozin V/F
each phase 17 times blood sampling, total 34 times blood sampling
Time frame: Pre-dose (Day1 0 hour), Day 1 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48, 72 hour
Gemigliptin metabolite(LC15-0636) AUClast
each phase 17 times blood sampling, total 34 times blood sampling
Time frame: Pre-dose (Day1 0 hour), Day 1 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48, 72 hour
Gemigliptin metabolite(LC15-0636) Cmax
each phase 17 times blood sampling, total 34 times blood sampling
Time frame: Pre-dose (Day1 0 h), Day 1 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48, 72 hour
Gemigliptin metabolite(LC15-0636) AUCinf
each phase 17 times blood sampling, total 34 times blood sampling
Time frame: Pre-dose (Day1 0 hour), Day 1 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48, 72 hour
Gemigliptin metabolite(LC15-0636) t1/2
each phase 17 times blood sampling, total 34 times blood sampling
Time frame: Pre-dose (Day1 0 hour), Day 1 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48, 72 hour
Gemigliptin metabolite(LC15-0636) metabolic ratio
each phase 17 times blood sampling, total 34 times blood sampling
Time frame: Pre-dose (Day1 0 hour), Day 1 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48, 72 hour
No study locations are listed for this record.
Plan to share: No
No publications or documents are linked to this record.
Start is estimated for Oct 2020; primary completion for Mar 2021, 5 months later.
How these figures are worked out, and which studies are left out of them.
This study is status unknown, as verified in Sep 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.